Anaveon: Anaveon announces IND approval of ANV600-001 (EXPAND) Phase

ANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential BASEL, Switzerland, May 29, 2024 (GLOBE NEWSWIRE) - Anaveon, a clinical stage, immuno-oncology company, today announced that its Investigational New Drug (IND) application to conduct a Phase I/II study evaluating [...]